Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 3/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6679628 | 0.81 | TSHR (0.57) | CA1CA2CA12CA4CA7 | |
| SCHEMBL29657286 | 0.81 | TSHR (0.57) | CA1CA2CA12CA4CA7 | |
| SCHEMBL19355318 | 0.81 | TSHR (0.57) | CA1CA2CA12CA4CA7 | |
| SCHEMBL11078734 | 0.81 | POLB (0.51) | TAAR1CA1CA2CA12CA4 | |
| SCHEMBL19314294 | 0.81 | TSHR (0.57) | CA1CA2CA12CA4CA7 | |
| SCHEMBL15328772 | 0.79 | AGTR1 (0.50) | CA1CA2CA12CA4CA7 | |
| SCHEMBL1473451 | 0.79 | CA1 (0.48) | TAAR1CA1CA2CA12CA4 | |
| SCHEMBL8423186 | 0.79 | CA1 (0.48) | TAAR1CA1CA2CA12CA4 | |
| SCHEMBL15328802 | 0.79 | AGTR1 (0.50) | CA1CA2CA12CA4CA7 | |
| SCHEMBL30317538 | 0.79 | CA1 (0.48) | TAAR1CA1CA2CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725942-A1 | COMPOUNDS ACTIVE ON CYCLIN D1 PATHWAY AND THEIR USE | Sibylla Biotech S.p.A. (IT) | 2026-04-15 | — | — | EP | disclosed |
| US-11021465-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-06-01 | — | — | US | disclosed |
| US-11021465-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-06-01 | — | — | US | disclosed |
| US-11008305-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-05-18 | — | — | US | disclosed |
| US-11008305-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3459942-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3459942-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2020-12-30 | — | — | EP | disclosed |
| CN-106977495-B | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2020-08-04 | — | — | CN | disclosed |
| US-20200109130-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-04-09 | — | — | US | disclosed |
| US-20200062732-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-02-27 | — | — | US | disclosed |
| US-20130281431-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
| US-20130281431-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
| EP-1037876-A1 | BIPHENYL DERIVATIVES AS PHARMACEUTICALS | Novartis AG (CH) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999023073-A1 | BIPHENYL DERIVATIVES AS PHARMACEUTICALS | NOVARTIS AG (CH) | 1999-05-14 | — | — | WO | disclosed |
| US-4897109-A | ACYLAMINE DERIVATIVE | CIBA-GEIGY CORPORATION (US) | 1990-01-30 | — | — | US | disclosed |
| US-4791098-A | 2-methyl-3-(p-methylphenyl)propionitrile, preparation and use thereof as scent | BASF AKTIENGESELLSCHAFT (DE) | 1988-12-13 | — | — | US | disclosed |
| EP-0270841-A2 | 2-Methyl-3-(para-methyl-phenyl) propionitrile, its preparation and use as a perfuming agent | BASF Aktiengesellschaft (DE) | 1988-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200109130-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | TAAR1 4636/4885CA1 4563/4885CA2 2979/4885 |
| US-11008305-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | TAAR1 4636/4885CA1 4563/4885CA2 2979/4885 |
| US-20200062732-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | TAAR1 4636/4885CA1 4563/4885CA2 2979/4885 |
| US-20130281431-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | TAAR1 4636/4885CA1 4563/4885CA2 2979/4885 |
| US-11021465-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | TAAR1 4636/4885CA1 4563/4885CA2 2979/4885 |
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | TAAR1 4408/4885CA1 3677/4885CA2 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.